ScholarLens Back to search
2019•Journal of Pharmacokinetics and PharmacodynamicsRequires access

Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy

Daniela J. Conrado, Jane Larkindale, Alexander K. Berg, Micki Hill, Jackson K. Burton, Keith R. Abrams, Richard Ted Abresch, Abby Bronson, Douglass S. Chapman, Michael J. Crowther, Tina Duong, Heather Gordish‐Dressman, Lutz O. Harnisch, Erik Henricson, Sarah Kim, Craig M. McDonald, Stephan Schmidt, Camille Vong, Xiaoxing Wang, Brenda L. Y. Wong, Florence H. Yong, Klaus Romero

Open publisher page 22 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 22 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Duchenne muscular dystrophy, Regulatory science, Drug development, Clinical trial, Drug, Risk analysis (engineering), Food and drug administration, Medicine

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy — Research Paper | ScholarLens